Centergate's Huasu obtains amended production license, passes GMP inspection

Beijing Centergate Technologies Holding (SZSE:000931) announced its subsidiary, Beijing Huasu Pharmaceutical, received an updated "Drug Production License" and a "GMP Compliance Inspection Notice" from the Beijing Drug Administration. The license update allows Beijing Huasu to include the production of "raw material drug (biphenylbenzylazole)" at its Cangzhou location. A subsequent GMP inspection confirmed the biphenylbenzylazole production line meets required standards. The company states that the license and inspection outcomes will improve its product structure and market competitiveness. While the company believes this will have a positive impact, long term impact is difficult to ascertain due to the market environment.